ImageneBio, Inc. Operating Lease Cost
ImageneBio, Inc. (IMA) reported Operating Lease Cost of $1.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-10
- ImageneBio, Inc. operating lease, cost for fiscal 2025 was $1.50M, a 200.00% increase from fiscal 2024.
- ImageneBio, Inc. operating lease, cost for fiscal 2024 was $500.00K, a 78.41% decline from fiscal 2023.
- ImageneBio, Inc. operating lease, cost for fiscal 2023 was $2.32M, a 31.29% increase from fiscal 2022.
- ImageneBio, Inc. operating lease, cost for fiscal 2022 was $1.76M, a 4.19% increase from fiscal 2021.
| Period end | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.50M 10-K · filed 2026-03-10 | |
| 2024-12-31 | $500.00K 10-K · filed 2026-03-10 | $2.76M 10-K · filed 2025-03-06 |
| 2023-12-31 | $2.32M 10-K · filed 2025-03-06 | |
| 2022-12-31 | $1.76M 10-K · filed 2024-03-12 | |
| 2021-12-31 | $1.69M 10-K · filed 2023-03-14 | |
| 2020-12-31 | $1.01M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |